2029 Immunity Immunization 
pharmaphorum
NOVEMBER 18, 2022
Dr John Lin, senior vice president of immune-oncology and head of bispecifics at Regeneron , said: “The collaboration will enable Regeneron and CytomX to combine our collective oncology expertise with two premier platforms […] to develop novel immunotherapies and research their potential to transform patient lives.”.
Express Pharma
FEBRUARY 21, 2024
billion by 2029. “ There are multiple Phase III studies for the ADC in frontline NSCLC in combination with immune checkpoint inhibitors such as Merck’s Keytruda (pembrolizumab) or AstraZeneca’s Imfinzi (durvalumab). billion in 2023, and GlobalData projects it to surpass $14 billion by 2029.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
JUNE 12, 2023
In 2022, the FDA awarded VX-548 breakthrough therapy and fast-track designations for post-operative pain, and the drug is forecast to reach sales of $416m by 2029. CB1 is predominantly found in the central and peripheral nervous system, whereas CB2 is primarily located in immune cells.
European Pharmaceutical Review
JANUARY 2, 2024
According to the research, the global cell and gene therapy market is predicted to value $80 billion by 2029. AstraZeneca highlighted that beneficially, the Gracell FasTCAR platform significantly shortens manufacturing time, enhances T cell fitness and could improve the effectiveness of autologous CAR-T treatment in patients.
European Pharmaceutical Review
AUGUST 30, 2022
1 This novel approach has been found to trigger robust protective immune responses at the predominant sites of pathogen infection. million by 2029, up from $122.287 million in 2021. Recent studies indicate that mucosal delivery of vaccines provides a better, longer-lasting effect than the traditional injection route.
Pharmaceutical Technology
JULY 8, 2022
Moreover, a deeper understanding of immune evasion by cancer cells may provide novel sensitization strategies to further enhance the clinical response of BiTEs. . Currently, there are 110 BiTEs in oncology clinical trials, with seven in Phase III and three in pre-registration.
European Pharmaceutical Review
NOVEMBER 16, 2023
billion by 2029. 2 One of the challenges that we have in treating cancer is that the human immune system is highly complex. This requires modulating different components of the human immune system in a way that can address different patient segments, as the immune system is dysregulated in different ways across different tumour types.
Expert insights. Personalized for you.
105 
Let's personalize your content